Kornimate/medical-research-clean huggingface dataset:
gene expression profiles in chronic periodontitis

Conditions: Chronic Periodontitis

Summary: current concepts of the causes of periodontitis implicate a bacterial infection as the primary cause of the disease. several bacterial species residing in a biofilm on tooth surfaces are closely associated with periodontitis. chronic periodontitis (cp) is initiated and sustained by bacterial plaque, but host defense mechanisms play an integral role in its pathogenesis. gene expression profiling is a powerful means of generating comprehensive genome-level data sets on diseases such as cancer, asthma, rheumatoid disorders and periodontitis, and provides significant insight information for these diseases. gene expression profiling may provide an evidence for involving genes in the pathogenesis of cp and generate further information other than clinical signs and symptoms of cp. the aim of this study was to identify gene-expression patterns of patients with chronic periodontitis by whole-transcriptome gene-expression analyses.


Eligibility criteria:
inclusion criteria: 1. cp patients had at least 20 teeth exhibiting \>30% of measured sites with \>5mm clinical attachment loss. 2. had bleeding on probing (bop) at \>50% of the proximal sites. exclusion criteria: 1. had any known systemic diseases that can influence the periodontal status, oral diseases other than chronic periodontitis and ongoing orthodontic therapy. 2. history of hepatitis, hiv infection, or diabetes; requirement for antibiotic prophylaxis, pregnancy or lactation; and long-term use of anti-inflammatory drugs. 3. should be free of systemic diseases 4. individuals had to be older than 18 years of age.

Keywords: chronic periodontitis genetics microarray analysis gingiva genes inflammation
emulsification of different viscosity silicone oil after complicated retinal detachment surgery

Conditions: Retinal Detachment Rhegmatogenous

Summary: silicone oil has been used as a surgical tool in complicated retinal detachment surgery. there are some complications occurring in pars plana vitrectomy with silicone oil tamponade. silicone oil emulsification is one of the complication that may result in severe sequels that are difficult to treat. it is believed that low viscosity silicone oil has more risk to develop emulsification than high viscosity silicone oil. up to now, however, there is no conclusive guideline that which types of silicone oil is suitable for these complicated retinal detachment surgeries and what is the appropriate time to remove the oil. this prospective study aims to study the silicone oil emulsification comparing between low viscosity and high viscosity silicone oil after complicated retinal detachment surgery.

silicone oil has been used as a surgical tool in retinal detachment surgery since 1962. the national eye institute silicone study demonstrated the superiority of silicone oil compared with sulfur hexafluoride, and its comparability with perfluoropropane, for the treatment of complicated retinal detachment associated with advanced proliferative vitreoretinopathy. there are some complications occurring in pars plana vitrectomy with silicone oil tamponade. these complications may occur during surgery and after the surgery. silicone oil emulsification is one of the complication that may result in severe sequels including band-shaped keratopathy, complicated glaucoma and retinopathy that are difficult to treat. the commonly used silicone oil includes low viscosity and high viscosity type. it is believed that low viscosity silicone oil has more risk to develop emulsification than high viscosity silicone oil. up to now, however, there is no conclusive guideline that which types of silicone oil is suitable for these complicated retinal detachment surgeries and what is the appropriate time to remove the oil. retrospective medical review of these patients using 1000-vs 5000-centistoke silicone oil demonstrated that anatomic and visual acuity outcomes, as well as complication rates including emulsification, were similar in both groups. to the best of authors' knowledge, there has been no prospective study on this subject. this study aims to study the silicone oil emulsification comparing between low viscosity and high viscosity silicone oil after complicated retinal detachment surgery.

Eligibility criteria:
inclusion criteria: * patients with diagnosis of complicated retinal detachment who underwent pars plana vitrectomy with intravitreal silicone oil tamponade * age ≥ 18 years * sign informed consent form exclusion criteria: * inflammatory eye diseases i.e. uveitis * corneal scar * history of scleral buckling procedure * history of using surfactant drugs * glaucoma

Keywords: silicone oil emulsification retinal detachment surgery
a study of daratumumab, bortezomib, lenalidomide and dexamethasone (dvrd) followed by ciltacabtagene autoleucel versus daratumumab, bortezomib, lenalidomide and dexamethasone (dvrd) followed by autologous stem cell transplant (asct) in participants with newly diagnosed multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is to compare the efficacy of daratumumab, bortezomib, lenalidomide and dexamethasone (dvrd) followed by ciltacabtagene autoleucel versus daratumumab, bortezomib, lenalidomide and dexamethasone (dvrd) followed by autologous stem cell transplant (asct) in newly diagnosed multiple myeloma patients.

multiple myeloma (mm) is a malignant plasma cell disorder characterized by the production of monoclonal immunoglobulin (ig) proteins or protein fragments (m proteins) that have lost their function. jnj-68284528 (ciltacabtagene autoleucel \[cilta-cel\]) is an autologous chimeric antigen receptor t cell (car-t) therapy that targets b-cell maturation antigen (bcma) that is being evaluated to treat participants with multiple myeloma. the primary hypothesis is that in transplant-eligible participants with newly diagnosed multiple myeloma (ndmm), cilta-cel will significantly improve progression-free survival (pfs) and sustained mrd-negative cr rate compared with autologous stem cell transplant (asct). approximately 750 participants (375 per arm) will be randomly assigned in a 1:1 ratio into 2 arms.

Eligibility criteria:
inclusion criteria: * participants with documented ndmm according to imwg diagnostic criteria, for whom high-dose therapy and asct are part of the intended initial treatment plan. * measurable disease, as assessed by central laboratory, at screening as defined by any of the following: 1. serum monoclonal paraprotein (m-protein) level ≥1.0 g/dl or urine m-protein level ≥200 mg/24 hours; or 2. light chain mm without measurable disease in serum or urine: serum ig free-light chain (flc) ≥10 mg/dl and abnormal serum ig kappa lambda flc ratio. * ecog performance status of grade 0 or 1 * clinical laboratory values within prespecified range. exclusion criteria: * prior treatment with car-t therapy directed at any target. * any prior bcma target therapy. * any prior therapy for mm or smoldering myeloma other than a short course of corticosteroids * received a strong cytochrome p450 (cyp)3a4 inducer within 5 half-lives prior to randomization * received or plans to receive any live, attenuated vaccine (except for covid-19 vaccines) within 4 weeks prior to randomization. * known active, or prior history of central nervous system (cns) involvement or clinical signs of meningeal involvement of mm * stroke or seizure within 6 months of signing informed consent form (icf)

Keywords: cellular therapy car-t therapy bcma car-t newly diagnosed multiple myeloma
study of epigallocatechin-3-gallate (egcg) for supportive and symptomatic management in patients with esophageal cancer

Conditions: Esophageal Obstruction

Summary: the main symptom of patients with advanced esophageal cancer is eating obstruction. in clinical practice, patients need to wait for a long time before anti-tumor treatment, which will lead to a rapid decline in the quality of life and nutritional status of patients, and severe patients sometimes need to place nasointestinal feeding tubes or endoscopic stents. egcg has been shown to have antioxidant, anti-inflammatory and anti-tumor effects . the complex effects of egcg may improve esophageal obstruction during the waiting period before antineoplastic therapy. the purpose of this phase i study was to explore the safety, recommended dose and preliminary efficacy of egcg solution in the treatment of esophageal obstruction.


Eligibility criteria:
inclusion criteria: * confirmed pathological esophageal squamous cell carcinoma * ≥18 years old * the eastern cooperative oncology group performance status (ecog ps) 0-1 * no previous anti-tumor treatment * no esophageal bleeding or fistula * adequate hemocyte count, normal hepatic and renal functions * esophageal obstruction classified as grade 2 or grade 3 according to stooler's dysphagia score exclusion criteria: * lactating or pregnant women * known hypersensitivity or allergy to any kind green tea extract * placement of small intestinal feeding tube or endoscopic stent treatment * unable or refusing to take oral liquids

Keywords: egcg esophageal obstruction supportive and symptomatic management
using saliva stimulation to immediately improve heart failure inpatient's thirst sensation

Conditions: Heart Failure; Thirst; Saliva

Summary: the purpose of this study is to using saliva stimulation to immediately improve heart failure inpatient's thirst sensation.

after being informed about the study and potential risks, all patients giving written informed consent will screening period to determine eligibility for study entry. patients who meet the eligibility requirements will be randomize in a double-blind manner (participant and researcher) in a 1:1 ratio to experimental group (lemonade ice cubes) or the control group (water ice cubes).

Eligibility criteria:
inclusion criteria: * 1. hospital stay for more than 24 hours; * 2. nyha iii-iv; * 3. oral mucosa is intact, without ulcers or wounds; * 4. consciousness and normal cognitive function; * 5. those who are more than 20 years old and can answer the questionnaire in chinese or taiwanese verbally or in writing; * 6. normal swallowing function; * 7. stable vital signs and maintain systolic blood pressure above 90mmhg; * 8. those who need to limit water according to doctor's advice exclusion criteria: * 1. those with endotracheal tube and respirator; * 2. those with indwelling nasogastric tube; * 3. those who fasted according to the doctor's advice; * 4. those who were diagnosed with dry syndrome

Keywords: heart failure thirst saliva stimulation
prevention of incisional hernia with biosynthetic mesh at the site of temporary ileostomy closure (princess)

Conditions: Incisional Hernia

Summary: prophylactic mesh reinforcement of the abdominal wall at the site of temporary ileostomy closure is effective in preventing postoperative incisional hernia. this prospective, multicenter, observational study will evaluate performance of phasix biosynthetic mesh when used to reinforce fascial closure .


Eligibility criteria:
inclusion criteria: * subjects will be informed about the study, and will have read; understood and signed the informed consent * subjects of either gender that are at least the age of 18 years * subjects will be undergoing ileostomy reversal with retromuscular placement technique of the phasix biosynthetic mesh reinforcement exclusion criteria: * subjects who, in the surgeon's opinion, would have a difficult time comprehending or complying with the requirements of the study * subjects with parastomal hernia or midline incisional hernia * subjects who required midline laparotomy during ileostomy reversal
clinical and economic outcomes of patients utilizing combination therapy for enlarged prostates: a henry ford database assessment

Conditions: Prostatic Hyperplasia

Summary: this retrospective study aims to assess the clinical and economic impact of early initiation of 5-alpha-reductase inhibitor (5ari) therapy in patients with enlarged prostate (ep) receiving 5ari monotherapy or combination therapy with an alpha-blocker (ab) compared to late initiation of 5ari therapy in patients receiving combination therapy. the henry ford health system databases will be utilized for this study (2000-2008).


Eligibility criteria:
inclusion criteria: * males * aged 50 years or older * medical claim of ep * prescription claim(s) for either a 5ari or both 5ari and ab (provided both are within 180 days of index date) * continuously eligible for 3 months prior to and at least 5 months after their index prescription date. exclusion criteria: * patients with prostate or bladder cancer * any prostate-related surgical procedure within 5 months of index date * prescription claim for finasteride indicative of male pattern baldness; ab monotherapy only; initiation of 5ari occurring more than 180 days after initiation of ab

Keywords: enlarged prostate, 5-alpha-reductase inhibitor, alpha-blocker, acute urinary retention, surgery, early, costs benign prostatic hyperplasia
targeted tdcs to enhance speech-language treatment outcome in persons with chronic post-stroke aphasia.

Conditions: Stroke; Aphasia

Summary: 62 patients who are one year post stroke and have aphasia as a result of that stroke will be recruited. participants will have 4 assessment sessions and 15 treatment sessions. the tdcs will be to right inferior frontal gyrus (ifg) (25 active, 25 sham) for 15 days. a combined semantic feature analysis/phonological components analysis treatment will be paired with the stimulation. two assessment sessions will be pretreatment, 1 session immediately post-treatment, and 1 session at 3 months follow-up.

our long-term goal is to develop safe and effective treatments for the communication problems of aphasia due to stroke that restore patients to higher levels of functioning, decrease disability, and promote higher quality of life. while language therapy for aphasia is effective, improvements are typically slow, and gains may be small. noninvasive brain stimulation has been suggested as a method to enhance outcomes from language therapy. this study will examine whether outcomes for language therapy with brain stimulation are different from outcomes for language therapy without brain stimulation in people with aphasia. our central hypotheses are (1) targeted right hemisphere hdtdcs (rh-hd-tdcs) administered in combination with language treatment will result in greater changes in naming accuracy than language treatment with the sham rh-hd-tdcs (2) rh-hd-tdcs plus language treatment will result in greater increases in communication within the affected hemisphere compared to language treatment plus sham rh-hd-tdcs (3) rh-hd-tdcs plus language treatment will result in greater increases in perilesional areas working together immediately post-treatment compared to language treatment plus sham rh-hd-tdcs

Eligibility criteria:
inclusion criteria: 1. aged 25-85 2. must be greater than 6 months post-stroke 3. must have a diagnosis of aphasia based on impaired performance on the western aphasia battery-revised, boston naming test, or during discourse production 4. must be left-hemisphere dominant as demonstrated by aphasia onset subsequent to left hemisphere damage 5. must be stimulable for naming exclusion criteria: 1. comorbid neurological disease. 2. damage to the anterior right hemisphere. 3. significant mood disorder. 4. substance/alcohol dependence or abuse within the past year 5. presence of any implanted electrical device or contraindications to tdcs or mri 6. recent medical instability (within 4 weeks) 7. pregnancy

Keywords: stroke aphasia brain stimulation communication problems speech and language therapy
cap-fitted colonoscopy: a randomized, tandem colonoscopy study of adenoma miss rates

Conditions: Polyps

Summary: this is a test in which a thin, black, flexible tube with a lighting system on the end is passed through the anus, into the rectum, in order to examine the large bowel or intestine, also called the colon. colonoscopy is a very good test for examining the colon for polyps (warty growths that can turn into cancer), but it is not perfect. in fact, about 30% of polyps that are under 5 mm (about 1/5 of an inch) in size are missed during colonoscopy because they are hiding behind folds and bends in the colon. this research study is being done to determine if performing colonoscopy with a cap on the tip of the colonoscope will reduce the miss rate for polyps. a cap is a clear plastic hood that fits on the tip of the colonoscope and sticks out about 1/3 of an inch. during colonoscopy, the cap can be pressed against a fold or ridge in order to flatten it, so that the lining on the other side can be more easily seen. this may reduce the miss rate for colon polyps.

patient will undergo tandem colonoscopy on the same day using propofol sedation. patients will undergo one colonoscopy without the cap and a second colonoscopy with the cap on. we will endeavor to keep the total examination time equal between the groups and approximately six minutes. the order in which patients receive the two colonoscopies (i.e. cap or without cap first) will be randomized. any polyps detected during the first colonoscopy will be removed during that procedure. during the withdrawal phase, the time for examination will be measured with a stopwatch, and the stopwatch will be stopped at any time a polyp is located and restarted when the polyp has been removed and retrieved. the stopwatch will also be stopped for suctioning fluid or washing debris from the colon surface. any polyp detected and removed during the first colonoscopy will be counted as the detection for that procedure. during the second colonoscopy, all polyps will also be removed when detected. any polyp identified and removed during the second procedure will be counted as a miss for the first procedure. all polyps will be sent separately for pathologic evaluation. the time required to remove and retrieve polyps with and without the cap on will be measured using a stopwatch as a secondary end point. the primary end point will be the miss rate for colonoscopy with the cap and colonoscopy without the cap.

Eligibility criteria:
inclusion criteria: * 50 years of age or older, undergoing scheduled colonoscopy and able to give informed consent. exclusion criteria: * previous surgical resection of the colon or rectum * american society of anesthesiology class iii or higher * inflammatory bowel disease * current use of anticoagulants.

Keywords: miss rates
virtual reality based cognitive training program in mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: this study evaluates efficacy and safety of virtual reality (vr)-based cognitive training program in amnestic mild cognitive impairment.

this study is a single-blind, randomized, controlled, two-period crossover trial. the intervention is done twice a week for 6 weeks. there are two arms. during the first period, participants were randomized to receive either vr-based cognitive training or usual care. after a 2-week washout period, the groups were crossed over to receive the alternative treatment for 6 weeks.

Eligibility criteria:
inclusion criteria: 1. aged 50-85 2. a memory complaint by a participant or caregiver 3. objective memory decline as defined by a delayed recall score of verbal learning test or logical memory worse than 1.0 standard deviations (sd) below age and education-adjusted normative mean 4. mmse score better than1.5 sd below age and education-adjusted normative means 5. global clinical dementia rating (cdr) scale of 0.5 and memory score of cdr 0.5 or 1 6. preserved activities of daily living (adl), as defined by korean instrumental activities of daily living \< 0.4 7. not demented 8. hachinski ischemic score ≤ 4 9. can read and write korean 10. brain mri or ct showing no other diseases capable of producing cognitive impairment 11. having a reliable informant who could provide investigators with the requested information. 12. provide written informed consent exclusion criteria: 1. participated in another clinical trial within the past 4 weeks 2. other serious or unstable medical disease such as acute or severe asthma, severe or unstable cardiovascular disease, active gastric ulcer, severe liver disease, or severe renal disease 3. a clinically significant laboratory abnormality, such as an abnormal thyroid function test, abnormal low levels of vitamin b12 or folate, and positive syphilis serology 4. a primary other neurodegenerative disorder 5. major psychiatric illness such as major depressive disorders 6. drug or alcohol addiction during the past 10 years 7. severe loss of vision, hearing, or communicative disability 8. malignancy within 5 years 9. any conditions preventing cooperation as judged by the study physician

Keywords: virtual reality
3d ultrasound for the imaging of lymph nodes in patients with breast cancer

Conditions: Breast Carcinoma

Summary: this early phase i studies how well a new 3d ultrasound (3d-us) imaging technology works in evaluating lymph nodes in patients with breast cancer. ultrasound uses high-frequency sound waves to generate images of the body.

primary objectives: i. conducting a pilot study to optimize the in vivo performance of the newly developed three-dimensional (3d)-ultrasound (us) technology. ii. evaluate the performance of the new 3d-us technique in differentiating benign from malignant lymph nodes in patients. iii. compare the performance of the new 3d-us method with conventional two-dimensional (2d)-us for localizing the clipped lymph nodes. outline: patients undergo 3d-us on study. patients who have a lymph node clip placed and undergoing neoadjuvant chemotherapy undergo imaging of the clipped node before surgery.

Eligibility criteria:
inclusion criteria: * patients with lymph node biopsy or lymph node clip placement as per routine clinical care. * age of 18 or older. exclusion criteria: * vulnerable subjects such as prisoners and adults lacking capacity to consent.
comparison of the combination of fenofibrate and 40 mg simvastatin versus 40 mg simvastatin monotherapy

Conditions: Cardiovascular Diseases

Summary: mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia. the overall objective of the study is to evaluate the efficacy and safety of combining fenofibrate and simvastatin in patients with mixed hyperlipidemia at risk of cardiovascular diseases.


Eligibility criteria:
inclusion criteria: * mixed dyslipidemia exclusion criteria: * diabetes, * known hypersensitivity to fenofibrate or simvastatin, * pregnant or lactating women, * contra-indication to fenofibrate or simvastatin, * unstable or severe cardiac disease.

Keywords: hyperlipidemia combined combination of fenofibrate and simvastatin